Detecting safety signals in subgroups

Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting

Volumn , Issue , 2014, Pages 289-319

  Chuang Stein, Christy ^a   Ii, Yoichi ^a   Kawai, Norisuke ^a   Komiyama, Osamu ^a   Kuribayashi, Kazuhiko ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85041305764     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b17846     Document Type: Chapter

References (58)

1. Amit O, Heiberger RM, Lane PW. Graphical approaches to the analysis of safety data from clinical trials. Pharmaceutical Statistics, 7: 20-35, 2008.
2. Assmann, SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis) uses of baseline data in clinical trials. Lancet, 355: 1064-1069, 2000.
3. Azuma A, Kudoh S, High prevalence of drug-induced pneumonia in Japan. Japan Medical Association Journal, 50(5): 405-411, 2007.
4. Breiman L, Freidman JH, Olshen RA, Stone CJ. Classification and Regression Trees, Wadsworth, Belmont, CA, 1984, Chapters 10-11, pp. 279-317.
5. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. The New England Journal of Medicine, 362(13): 1169-1171, 2010.
6. Chuang-Stein C, Beltangady M. Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies. Pharmaceutical Statistics, 10(1): 3-7, 2011.
7. Chuang-Stein C, Xia A. The practice of pre-marketing safety assessment in drug development. Journal of Biopharmaceutical Statistics, 23(1): 3-25, 2013.
8. Cochran WG. Some methods for strengthening the common chi-square tests. Biometrics, 10: 417-451, 1954.
9. Congressional Record-House. NIH Revitalization Act. Sec. 131, Inclusion of Women and Minorities in Clinical Research, 20 May, page H2623, 1993.
10. Crowe BJ, Xia HA, Berlin JA, Watson DJ, Shi H, Lin SL, Kuebler J et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: A report of the safety planning, evaluation, and reporting team. Clinical Trials, 6(5): 430-440, 2009.
11. Cui L, Hung HM, Wang SJ, Tsong Y. Issues related to subgroup analysis in clinical trials. Journal of Biopharmaceutical Statistics, 12: 347-358, 2002.
12. Cuzick J. Forest plots and the interpretation of subgroups. Lancet, 365: 1308, 2005.
13. Davis CE, Leffingwell DP. Empirical Bayes estimates of subgroup effects in clinical trials. Controlled Clinical Trials, 11: 37-42, 1990.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clinical Trials, 7(3): 177-188, 1986.
15. Egger M, Smith GD, Phillips AN. Meta-analysis: Principles and procedures. British Medical Journal, 315(7121): 1533-1537, 1997.
16. Fleming TR. Interpretation of subgroup analyses in clinical trials. Drug Information Journal, 29: 1681S-1687S, 1995.
17. Food and Drug Administration. Guidance for industry-Premarketing risk assessment. http://www.fda.gov/downloads/Drugs/GuidanceCompliance Regulatory Information/Guidances/UCM072002.pdf, 2005. Accessed January 10, 2014.
18. Food and Drug Administration. FDA Drug safety communication: Drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ucm213836.htm, 2010. Accessed January 10, 2014.
19. Food and Drug Administration. FDA Drug safety communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs). http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm, 2011. Accessed January 10, 2014.
20. Foster JC, Taylor JMG, Ruberg SJ. Subgroup identification from randomized clinical trial data. Statistics in Medicine, 30: 2867-2880, 2011.
21. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics, 41(2): 361-372, 1985.
22. Greenland S. Principles of multilevel modelling. International Journal of Epidemiology, 29: 158-167, 2000.
23. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics, 41: 55-68, 1985.
24. Hahn S, Williamson PR, Hutton JL, Garner P, Flynn EV. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. Statistics in Medicine, 19: 3325-3336, 2000.
25. Hardy RJ, Thompson SG. A likelihood approach to meta-analysis with random effects. Statistics in Medicine, 15: 619-629, 1996.
26. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet, 359: 1121-1122, 2002.
27. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21: 1539-1558, 2002.
28. Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D. PREDICT-1 (CNA106030): The first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharmaceutical Statistics, 7: 121-129, 2008.
29. Ioannidis JP, Patsopoulos NA. Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. British Medical Journal, 335: 914-916, 2007.
30. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T et al. Calcium plus vitamin D supplementation and the risk of fractures. The New England Journal of Medicine, 354: 669-683, 2006.
31. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists-The influence of values. The New England Journal of Medicine, 360(16): 1592-1595, 2009.
32. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis: Statistical briefing package for joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, and Pediatric Advisory Committee on December 10-11, 2008.
33. Li J, Mehrotra DV, An efficient method for accommodating potentially underpowered primary endpoints. Statistics in Medicine, 27: 5377-5391, 2008.
34. Li Z, Chuang-Stein C, Hoseyni C. The probability of observing negative subgroup results when the treatment effect is positive and homogeneous across all subgroups. Drug Information Journal, 41(1): 47-56, 2007.
35. Lipkovich I, Dmitrienko A, Denne J, Enas G. Subgroup identification based on differential effect search: A recursive partitioning method for establishing response to treatment in patient subpopulations. Statistics in Medicine, 30: 2601-2621, 2011.
36. Lipskly AM, Gaushe-Hill M, Vienna M, Lewis RJ. The importance of “Shrinkage” in subgroup analyses. Annals of Emergency Medicine, 55(6): 544-552, 2010.
37. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia, 49: 2087-2091, 2008.
38. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 359: 727-732, 2002.
39. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E et al. HLA-B*5701 screening for hypersensitivity to abacavir. The New England Journal of Medicine, 358: 568-579, 2008.
40. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute, 22: 719-748, 1959.
41. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. British Medical Journal, 332(7551): 1177-1181, 2006.
42. Nurminen M. Asymptotic efficiency of general noniterative estimators of common relative risk. Biometrika, 68: 525-530, 1981.
43. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study. Archives of General Psychiatry, 63(8): 865-872, 2006.
44. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: Proposed metrics and empirical evaluation. International Journal of Epidemiology, 37: 1148-1157, 2008.
45. Phillips EJ, Simon A. Mallal SA, HLA-B*1502 screening and toxic effects of carbamazepine. The New England Journal of Medicine, 365(7): 672-673, 2011.
46. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the western Australian HIV cohort study. Clinical Infectious Diseases, 43: 99-102, 2006.
47. Robins J, Greenland S, Breslow NE. A general estimator for the variance of the Mantel-Haenszel odds ratio. American Journal of Epidemiology, 124(5): 719-723, 1986.
48. Ruberg SJ, Chen L, Wang Y. The mean does not mean as much anymore: Finding subgroups for tailored therapeutics. Clinical Trials, 7: 574-583, 2010.
49. Sato T. On the variance estimator for the Mantel-Haenszel risk difference (letter). Biometrics, 45: 1323-1324, 1989.
50. Sidak Z. Rectangular confidence regions for the means of multivariate normal distributions. Journal of the American Statistical Association, 62: 626-633, 1967.
51. Tarone RE. On summary estimators of relative risk. Journal of Chronic Diseases, 34: 463-468, 1981.
52. Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART routines. Technical report, Mayo Clinic, Section of Biostatistics, 2011.
53. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-Reporting of subgroup analyses in clinical trials. The New England Journal of Medicine, 357: 2189-2194, 2007.
54. Whitehead A. Meta-Analysis of Controlled Clinical Trials, John Wiley & Sons, Ltd., Hoboken, NJ, 2002.
55. Wittes J. On looking at subgroups. Circulation, 119: 912-915, 2009.
56. Xia HA, Ma H, Carlin BP. Bayesian hierarchical modeling for detecting safety signals in clinical trials. Journal of Biopharmaceutical Statistics, 21(5): 1006-1029, 2011.
57. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. JAMA, 266: 93-98, 1991.
58. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. Journal of Acquired Immune Deficiency Syndromes, 45: 1-3, 2007.